Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protara TherapeuticsTARA -2.73%32 FCF Yield % is -28.58 as of Aug. 02, 2026. GuruFocus rates TARA with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Protara Therapeutics ranks worse than 72.06% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Protara Therapeutics FCF Yield % Related Terms
Protara Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Protara Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protara Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protara Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protara Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Protara Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protara Therapeutics (TARA) has a FCF Yield % of -28.58 as of Aug. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Protara Therapeutics and its competitors. According to the industry distribution chart, Protara Therapeutics ranks #1016 out of 1410 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Protara Therapeutics' FCF Yield % too high?
Protara Therapeutics' current FCF Yield % is -28.58. Based on the distribution chart, Protara Therapeutics ranks #1016 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Protara Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' FCF Yield % compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, Protara Therapeutics ranks #1016 out of 1410 companies for FCF Yield %. This places Protara Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Protara Therapeutics and its competitors. Protara Therapeutics's current FCF Yield % is -28.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (TARA) has a current FCF Yield % of -28.58. The current FCF Yield % is -28.58. Protara Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Protara Therapeutics (TARA), the current FCF Yield % is -28.58 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
32GF Score
Get the complete analysis for TARA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARA has been successfully added to your 
